LEUKEMIAS

Real-world data link vitamin D supplements to longer watch-and-wait time before CLL treatment, prompting fresh debate on delaying progression.

Oncologists debate BTK inhibitor choices in relapsed CLL, exploring when MRD testing matters, toxicity management, and insurance hurdles.

Triplet therapy ziftomenib plus venetoclax/azacitidine boosts MRD-negative remissions in relapsed NPM1-mutated AML, hinting at earlier use.

The T-cell immunotherapy Orca-T has gained FDA approval in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndromes (MDS).

Catherine Coombs, MD and oncologists weigh frontline CLL therapy choices, balancing BTK inhibitors vs fixed-duration venetoclax combinations as age, comorbidities, and new trial data guide decisions.

KOMET-007 data spotlight ziftomenib combos in newly diagnosed NPM1/KMT2A AML, detailing dosing, sequencing, and maintenance with 7+3 or aza/ven.

Early phase 2 results suggest 12-cycle pirtobrutinib–obinutuzumab yields high responses in untreated CLL with minimal cardiac effects.

FBEM conditioning in ALL alloHSCT yielded 92.1% 2-year OS and 14.3% relapse rate, with 0% 100-day NRM and manageable GVHD in 203 patients.

FDA granted RMAT designation to lasme-cel, a CD22-targeting allogeneic CAR-T, for R/R B-ALL, the first such therapy in a pivotal trial for this indication.

Off-the-shelf CD19 CAR T azer-cel earns FDA Fast Track after early trials show striking responses in refractory CLL/SLL and marginal zone lymphoma.

FDA approves Cavhanza, a nilotinib orally disintegrating tablet for adult Ph+ CML, enabling use with PPIs/H2RAs and meals for easier dosing.

Posttransplant revumenib maintenance in genetically defined AML shows promising survival and low relapse, with thrombocytopenia as key toxicity.

FLAIR finds ibrutinib‑rituximab matches FCR quality of life in untreated CLL over 4 years, with distinct adverse‑effect tradeoffs.

FDA fast tracks STX-0712, a CCR2-targeted CyTAC, as phase 1 trial enrolls to tackle relapsed/refractory CMML and monocytic AML.

New survey reveals CLL physicians and patients vary widely on post-BTK inhibitor tradeoffs, urging shared decisions beyond survival data.

Older men with CLL on BTK inhibitors face sharply higher atrial fibrillation risk, shaping drug choice and prompting stronger cardiovascular screening and monitoring.

Decade-long trial shows continuous ibrutinib delivers durable survival in high-risk or older CLL, with emerging uMRD and manageable cardiac risks.

FDA grants orphan status to CLN‑049, an FLT3xCD3 T‑cell engager in phase 1, for relapsed/refractory patients with AML.

FDA approves an all-oral treatment for newly diagnosed acute myeloid leukemia, enhancing options for patients ineligible for intensive chemotherapy.

Mipletamig plus venetoclax and azacitidine delivers high remission rates and no CRS in early RAINIER trial, boosting hopes for unfit AML patients.

The second-generation T-cell immunotherapy Orca-Q demonstrated encouraging outcomes in an ongoing phase 1 trial.

FDA designates TERN-701 as breakthrough therapy for heavily pretreated Ph+ CP-CML, as allosteric BCR-ABL inhibitor shows rapid deep molecular responses and tolerable safety.

Longer follow-up from the NMDP's ACCESS trial emphasizes the opportunity to use mismatched stem cell donors in more diverse patient populations.

UK trial data show TP53 and unmutated IGHV outperform copy-number complexity for CLL prognosis, guiding smarter molecular risk stratification.

New CMML molecular framework links genomic classes and iCPSS scoring to predict outcomes and guide optimal stem cell transplant timing.